Efficacy of GnRH-α combined with Mirena in the treatment of adenomyosis and its impact on ovarian function

Abstract

Objective : To discuss and analyze the clinical effects and changes of ovarian function after GnRH-α combined with Mirena treatment in patients with adenomyosis. Methods: The research subjects in this study were all adenomyosis patients (60 cases) who were admitted to our hospital from January 2020 to June 2022. They were randomly divided into control group (30 cases, receiving Mirena treatment) and observation group (30 cases, receiving GnRH-α combined with Mirena treatment). Compare the relevant indicators of the two groups. Results: After treatment, the uterine volume of the observation group and the control group were smaller than before treatment, the thickness of endometrium was thinner than before treatment, the VAS score, PBAC score, serum FSH, LH, E2 levels were all lower than before treatment, the serum AMH level, and various FSFI scores were higher than before treatment, and the trend of the former was more obvious. The comparison of the total incidence of adverse reactions between the observation group and the control group showed that the former was lower (all P < 0.05 ). Conclusion: The application of GnRH-α combined with Mirena in patients with adenomyosis can reduce the amount of menstrual bleeding, reduce the volume of the uterus, relieve pain, promote the recovery of ovarian function, improve the quality of sexual life, and have high safety. It is worthy of extensive follow-up application.